Date: 2017-01-18
Type of information: Clinical trial autorization
phase: 1
Announcement: clinical trial authorization
Company: Genexine (Republic of Korea)
Product: GX-G6
Action
mechanism: Glucagon-like Peptide (GLP) analogue. GX-G6 is long-acting GLP-1 based on Genexine’s proprietary hyFc Platform technology for type 2 diabetes (T2D) targeting both weekly and twice-monthly regimen compared to conventional daily therapeutics. GX-G6 was designated as the Korean government project supported by Ministry of Health and Welfare and Ministry of Trade, Industry, and Energy
Disease: type 2 diabetes
Therapeutic area: Metabolic diseases
Country: Germany
Trial details:
Latest
news: * On January 18, 2017, Genexine, a clinical stage biotechnology company developing innovative biologics focused on immuno-oncology and metabolic diseases, announced that GX-G6, long-acting glucagon-like peptide-1 (GLP-1), received Phase I IND approval from The Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) in Germany. Phase I clinical trial is scheduled to begin in the first half of 2017 with plans to enroll up to 48 healthy volunteers in Germany.
